Page 10 - BOPHELO - Life - 2026

Africa and the Quest

for an HIV Vaccine

South Africa has taken a historic step in the global effort The BRILLIANT-011 HIV vaccine trial, led by the
to develop an HIV vaccine targeting strains circulating South African Medical Research Council (SAMRC) in
in Southern Africa, with the launch of the BRILLIANT partnership with the Desmond Tutu Health Foundation
011 first-in-human clinical trial at the Desmond Tutu HIV and the Wits Health Consortium, is being described as
Foundation (DTHF) site at Groote Schuur Hospital. a historic milestone. It is the first HIV vaccine to enter a
first-in-human clinical trial designed by African scientists
For more than four decades, HIV has remained one of using vaccine products originally discovered in African
the world’s most formidable public health challenges. trial participants and tailored specifically to HIV strains
Despite remarkable advances in treatment and circulating in Southern Africa.
prevention, a safe and effective vaccine has remained
elusive. Now, a groundbreaking clinical trial led by African What sets BRILLIANT-011 apart from previous HIV vaccine
scientists is reshaping the global HIV vaccine landscape efforts is both its scientific strategy and its context. HIV’s
and positioning South Africa and the continent at the ability to mutate rapidly has long frustrated vaccine
forefront of innovation. development, allowing the virus to evade immune

8 THE SOUTH AFRICAN MEDICAL RESEARCH COUNCIL